The role of dopamine receptors in the neurotoxicity of methamphetamine

Journal of Internal Medicine

Volumn 273, Issue 5, 2013, Pages 437-453

  Ares Santos, S ^a,b   Granado, N ^a,b,c   Moratalla, R ^a,b  

^a INSTITUTO CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Amphetamine derivatives; Designer drugs; Dopamine; Drug addiction; Parkinson's disease; Psychostimulants

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; METHAMPHETAMINE; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; BODY TEMPERATURE; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; HUMAN; HYPOTHERMIA; LIPID PEROXIDATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TURNOVER TIME;

ANIMALS; DOPAMINE AGENTS; HUMANS; METHAMPHETAMINE; MICE; NEUROTOXICITY SYNDROMES; OXIDATIVE STRESS; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 84876740411     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12049     Document Type: Article

References (152)

1. UNODC. World Drug Report 2012. United Nations publication, Sales No. E.12.XI.1, 2012.
2. Cadet JL, Krasnova IN. Molecular bases of methamphetamine-induced neurodegenerationm, 1st edn. Int Rev Neurobiol, Elsevier Inc.; 2009; 88: 101-19.
3. Ares-Santos S, Granado N, Oliva I et al. Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol Dis 2012; 45: 810-20.
4. Granado N, Ares-Santos S, O'Shea E, Vicario-Abejón C, Colado MI, Moratalla R. Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine. Neurotox Res 2010; 18: 48-58.
5. Granado N, Lastres-Becker I, Ares-Santos S et al. Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia 2011; 59: 1850-63.
6. Granado N, Ares-Santos S, Oliva I et al. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis Elsevier Inc.; 2011; 42: 391-403.
7. Hirata H, Cadet JL. P53-Knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies. J Neurochem 1997; 69: 780-90.
8. Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED. Treatment of mice with methamphetamine produces cell loss in the substantial nigra Tyrosine Hydroxylase ICC. Brain Res 1996; 738: 172-5.
9. Hurtig HI, Trojanowski JQ, Galvin J et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54: 1916-21.
10. Darmopil S, Muñetón-Gómez VC, De Ceballos ML, Bernson M, Moratalla R. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA. Eur J Neurosci 2008; 27: 580-92.
11. Espadas I, Darmopil S, Vergaño-Vera E et al. l-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: Insights into regulation and function. Neurobiol Dis 2012; 48: 271-81.
12. Burke RE, Baimbridge KG. Relative loss of the striatal striosome compartment, defined by calbindin-D28k immunostaining, following developmental hypoxic-ischemic injury. Neuroscience 1993; 56: 305-15.
13. Figueredo-Cardenas G, Harris CL, Anderson KD, Reiner A. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types. Exp Neurol 1998; 149: 356-72.
14. Granado N, O'Shea E, Bove J, Vila M, Colado MI, Moratalla R. Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J Neurochem 2008; 107: 1102-12.
15. Granado N, Escobedo I, Shea EO, Colado MI. Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse 2008; 84: 80-4.
16. Hedreen JC, Folstein SE. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 1995; 54: 105-20.
17. Iravani MM, Syed E, Jackson MJ, Johnston LC, Smith LA, Jenner P. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur J Neurosci 2005; 21: 841-54.
18. Medina L, Figueredo-Cardenas G, Reiner A. Differential abundance of superoxide dismutase in interneurons versus projection neurons and in matrix versus striosome neurons in monkey striatum. Brain Res 1996; 708: 59-70.
19. Crittenden JR, Graybiel AM. Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front Neuroanat 2011; 5: 59.
20. Cadet JL, Ladenheim B, Hirata H et al. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse (New York, N.Y.) 1995; 21: 169-76.
21. Volkow ND, Chang L, Wang GJ et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377-82.
22. Volkow ND, Chang L, Wang GJ et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001; 21: 9414-8.
23. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35, 428. J Neurosci 1998; 18: 8417-22.
24. Wang G-J, Volkow ND, Chang L et al. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry 2004; 161: 242-8.
25. Granado N, Ares-Santos S, Moratalla R. Methamphetamine and Parkinson' s Disease. Parkinsons Dis 2013; doi:10.11555/2013/308052 (In press).
26. Callaghan RC, Cunningham JK, Sykes J, Kish SJ. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend, Elsevier Ireland Ltd; 2012; 120: 35-40.
27. Chang L, Alicata D, Ernst T, Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction (Abingdon, England) 2007; 102(Suppl): 16-32.
28. Paulus MP, Hozack NE, Zauscher BE et al. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology 2002; 26: 53-63.
29. Krasnova I, Cadet J. Methamphetamine toxicity and messengers of death. Brain Res Rev, Elsevier B.V. 2009; 60: 379-407.
30. Johnson JA, Johnson DA, Kraft AD et al. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 2008; 1147: 61-9.
31. Liang NY, Rutledge CO. Evidence for carrier-mediated efflux of dopamine from corpus striatum. Biochem Pharmacol 1982; 31: 2479-84.
32. Hansen JP, Riddle EL, Sandoval V et al. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 2002; 300: 1093-100.
33. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999; 22: 123-44.
34. Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 1998; 32: 117-31.
35. Imam SZ, Newport GD, Itzhak Y et al. Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J Neurochem 2001; 76: 745-9.
36. Ali SF, Imam SZ, Itzhak Y. Role of peroxynitrite in methamphetamine-induced dopaminergic neurodegeneration and neuroprotection by antioxidants and selective NOS inhibitors. Ann N Y Acad Sci 2005; 1053: 97-8.
37. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424-37.
38. Imam SZ, Newport GD, Duhart HM, Islam F, Slikker W, Ali SF. Methamphetamine-induced dopaminergic neurotoxicity and production of peroxynitrite are potentiated in nerve growth factor differentiated pheochromocytoma 12 cells. Ann N Y Acad Sci 2002; 965: 204-13.
39. Stephans SE, Yamamoto BK. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse (New York, N.Y.) 1994; 17: 203-9.
40. Nash JF, Yamamoto BK. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3, 4-methylenedioxymethamphetamine. Brain Res 1992; 581: 237-43.
41. Brown JM, Quinton MS, Yamamoto BK. Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite. J Neurochem 2005; 95: 429-36.
42. Jayanthi S, Deng X, Noailles P-AH, Ladenheim B, Cadet JL. Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J 2004; 18: 238-51.
43. Burrows KB, Gudelsky G, Yamamoto BK. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3, 4-methylenedioxymethamphetamine administration. Eur J Pharmacol 2000; 398: 11-8.
44. Gluck MR, Moy LY, Jayatilleke E, Hogan KA, Manzino L, Sonsalla PK. Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem 2001; 79: 152-60.
45. Brown JM, Yamamoto BK. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther 2003; 99: 45-53.
46. Antonelli MC, Guillemin GJ, Raisman-Vozari R et al. New strategies in neuroprotection and neurorepair. Neurotox Res 2012; 21: 49-56.
47. Stephans SE, Whittingham TS, Douglas AJ, Lust WD, Yamamoto BK. Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum. J Neurochem 1998; 71: 613-21.
48. Wagner GC, Carelli RM, Jarvis MF. Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion. Neuropharmacology 1986; 25: 559-61.
49. De Vito MJ, Wagner GC. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 1989; 28: 1145-50.
50. Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci 1998; 18: 4861-9.
51. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 1999; 19: 2424-31.
52. Albers DS, Sonsalla PK. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 1995; 275: 1104-14.
53. Hirata H, Ladenheim B, Carlson E, Epstein C, Lud J. Dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res 1996; 714: 95-103.
54. Itzhak Y, Martin JL, Ail SF. nNOS inhibitors attenuate methamphetamine-induced dopaminergic neurotoxicity but not hyperthermia in mice. NeuroReport 2000; 11: 2943-6.
55. Itzhak Y, Ali SF. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J Neurochem 1996; 67: 1770-3.
56. Klongpanichapak S, Govitrapong P, Sharma SK, Ebadi M. Attenuation of cocaine and methamphetamine neurotoxicity by coenzyme Q10. Neurochem Res 2006; 31: 303-11.
57. LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 1999; 19: 1484-91.
58. Docherty JR, Green AR. The role of monoamines in the changes in body temperature induced by 3, 4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol 2010; 160: 1029-44.
59. Hadlock GC, Webb KM, McFadden LM et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011; 339: 530-6.
60. Sparago M, Wlos J, Yuan J et al. Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse. J Pharmacol Exp Ther 1996; 279: 1043-52.
61. Series HG, Molliver ME. Immunocytochemical evidence for serotonergic neurotoxicity of N-ethyl-methylenedioxyamphetamine (MDE). Exp Neurol 1994; 128: 50-8.
62. Capela JP, Fernandes E, Remião F, Bastos ML, Meisel A, Carvalho F. Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. Neurotoxicology 2007; 28: 868-75.
63. Angoa-Pérez M, Kane MJ, Francescutti DM et al. Mephedrone, an abused psychoactive component of "bath salts" and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 2012; 120: 1097-107.
64. Yamamoto BK, Bankson MG. Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit Rev Neurobiol 2005; 17: 87-117.
65. Yamamoto BK, Moszczynska A, Gudelsky GA. Amphetamine toxicities: classical and emerging mechanisms. Ann N Y Acad Sci 2010; 1187: 101-21.
66. Cadet JL, Krasnova IN, Jayanthi S, Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 2007; 11: 183-202.
67. Gramage E, Rossi L, Granado N, Moratalla R, Herradón G. Genetic inactivation of pleiotrophin triggers amphetamine-induced cell loss in the substantia nigra and enhances amphetamine neurotoxicity in the striatum. Neuroscience 2010; 170: 308-16.
68. Colado MI, O'Shea E, Granados R, Murray TK, Green AR. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 1997; 121: 889-900.
69. Green AR, Mechan AO, Elliott JM, Shea EO, Colado MI. The pharmacology and clinical pharmacology of 3, 4- methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev 2003; 55: 463-508.
70. Aerts LA, Mallaret M, Rigter H. N-methyl-1-(1, 3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. Addict Biol 2000; 5: 269-82.
71. Johnson MP, Nichols DE. Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration. Pharmacol Biochem Behav 1989; 33: 105-8.
72. Johnson M, Hanson GR, Gibb JW. Effects of N-ethyl-3, 4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat. Biochem Pharmacol 1987; 36: 4085-93.
73. Karila L, Reynaud M. GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Anal 2011; 3: 552-9.
74. Carvalho M, Carmo H, Costa VM et al. Toxicity of amphetamines: an update. Arch Toxicol 2012; 86: 1167-231.
75. Gygi MP, Fleckenstein AE, Gibb JW, Hanson GR. Role of endogenous dopamine in the neurochemical deficits induced by methcathinone. J Pharmacol Exp Ther 1997; 283: 1350-5.
76. Rockhold RW, Carlton FB, Corkern R, Derouen L, Bennett JG, Hume AS. Methcathinone intoxication in the rat: abrogation by dextrorphan. Ann Emerg Med 1997; 29: 383-91.
77. De Bie RMA, Gladstone RM, Strafella AP, Ko J-H, Lang AE. Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. Arch Neurol 2007; 64: 886-9.
78. Colosimo C, Guidi M. Parkinsonism due to ephedrone neurotoxicity: a case report. Eur J Neurol 2009; 16: e114-5.
79. Sikk K, Taba P, Haldre S et al. Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure. Acta Neurol Scand 2010; 121: 237-43.
80. Sikk K, Taba P, Haldre S et al. Irreversible motor impairment in young addicts-ephedrone, manganism or both? Acta Neurol Scand 2007; 115: 385-9.
81. Stepens A, Logina I, Liguts V et al. A Parkinsonian syndrome in methcathinone users and the role of manganese. N Engl J Med 2008; 358: 1009-17.
82. Kelly JP. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011; 3: 439-53.
83. Varlibas F, Delipoyraz I, Yuksel G, Filiz G, Tireli H, Gecim NO. Neurotoxicity following chronic intravenous use of "Russian cocktail". Clin Toxicol (Philadelphia, Pa.) 2009; 47: 157-60.
84. Iqbal M, Monaghan T, Redmond J. Manganese toxicity with ephedrone abuse manifesting as parkinsonism: a case report. J Med Case Rep 2012; 6: 52.
85. Guilarte TR. Manganese and Parkinson's disease: a critical review and new findings. Environ Health Perspect 2010; 118: 1071-80.
86. Den Hollander B, Rozov S, Linden A-M, Uusi-Oukari M, Ojanperä I, Korpi ER. Long-term cognitive and neurochemical effects of "bath salt" designer drugs methylone and mephedrone. Pharmacol Biochem Behav 2012; 103: 501-9.
87. Kalivas PW, Duffy P, DuMars LA, Skinner C. Behavioral and neurochemical effects of acute and daily cocaine administration in rats. J Pharmacol Exp Ther 1988; 245: 485-92.
88. Kleven MS, Woolverton WL, Seiden LS. Lack of long-term monoamine depletions following repeated or continuous exposure to cocaine. Brain Res Bull 1988; 21: 233-7.
89. Ryan LJ, Martone ME, Linder JC, Groves PM. Cocaine, in contrast to d-amphetamine, does not cause axonal terminal degeneration in neostriatum and agranular frontal cortex of Long-Evans rats. Life Sci 1988; 43: 1403-9.
90. Sharma HS, Muresanu D, Sharma A, Patnaik R. Cocaine-induced breakdown of the blood-brain barrier and neurotoxicity. Int Rev Neurobiol 2009; 88: 297-334.
91. Cunha-Oliveira T, Rego AC, Oliveira CR. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev 2008; 58: 192-208.
92. Dietrich J-B, Mangeol A, Revel M-O, Burgun C, Aunis D, Zwiller J. Acute or repeated cocaine administration generates reactive oxygen species and induces antioxidant enzyme activity in dopaminergic rat brain structures. Neuropharmacology 2005; 48: 965-74.
93. Lee DK, Ahn SM, Shim Y-B, Koh WCA, Shim I, Choe ES. Interactions of dopamine D1 and N-methyl-D-aspartate receptors are required for acute cocaine-evoked nitric oxide efflux in the dorsal striatum. Exp Neurobiol 2011; 20: 116-22.
94. Bashkatova V, Meunier J, Vanin A, Maurice T. Nitric oxide and oxidative stress in the brain of rats exposed in utero to cocaine. Ann N Y Acad Sci 2006; 1074: 632-42.
95. Poon HF, Abdullah L, Mullan MA, Mullan MJ, Crawford FC. Cocaine-induced oxidative stress precedes cell death in human neuronal progenitor cells. Neurochem Int 2007; 50: 69-73.
96. Kleven MS, Seiden LS. Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum. Brain Res 1991; 557: 340-3.
97. Chen R. The role of exogenous testosterone in cocaine-induced behavioral sensitization and plasmalemmal or vesicular dopamine uptake in castrated rats. Neurosci Lett 2003; 351: 161-4.
98. Touriño C, Zimmer A, Valverde O. THC Prevents MDMA neurotoxicity in mice. PLoS One 2010; 5: e9143.
99. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95: 8268-73.
100. Chen Y, Buck J. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther 2000; 293: 807-12.
101. Beaulieu J, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63: 182-217.
102. Giros B, Sokoloff P, Martres MP, Riou JF, Emorine LJ, Schwartz JC. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 1989; 342: 923-6.
103. Monsma FJ, McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 1989; 342: 926-9.
104. De Mei C, Ramos M, Iitaka C, Borrelli E. Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. Curr Opin Pharmacol 2009; 9: 53-8.
105. Usiello A, Baik JH, Rougé-Pont F et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000; 408: 199-203.
106. Hadlock GC, Chu P, Walters ET, Hanson GR, Fleckenstein AE. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation. J Pharmacol Exp Ther 2010; 335: 207-12.
107. Darvas M, Palmiter RD. Restriction of dopamine signaling to the dorsolateral striatum is sufficient for many cognitive behaviors. Proc Natl Acad Sci USA 2009; 106: 14664-9.
108. Darvas M, Palmiter RD. Restricting dopaminergic signaling to either dorsolateral or medial striatum facilitates cognition. J Neurosci 2010; 30: 1158-65.
109. 109. Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry, Elsevier Inc. 2009; 66: 603-13.
110. Ortiz O, Delgado-García JM, Espadas I et al. Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null, Drd1a-/- mice and in hippocampal siRNA silenced Drd1a mice. J Neurosci 2010; 30: 12288-300.
111. Martín AB, Fernandez-Espejo E, Ferrer B et al.Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 2008; 33: 1667-79.
112. Murer MG, Moratalla R. Striatal signaling in L-DOPA-induced dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation. Front Neuroanat 2011; 5: 51.
113. Granado N, Ortiz O, Suárez LM et al. D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-Induced arc and zif268 expression in the hippocampus. Cereb Cortex (New York, N.Y.: 1991). 2008; 18: 1-12.
114. Rodrigues TB, Granado N, Ortiz O, Moratalla R. Metabolic interactions between glutamatergic and dopaminergic neurotransmitter systems are mediated through D 1 dopamine receptors. J Neurosci Res 2007; 3293: 3284-93.
115. Gangarossa G, Longueville S, De Bundel D et al. Characterization of dopamine D1 and D2 receptor-expressing neurons in the mouse hippocampus. Hippocampus 2012; 22: 2199-207.
116. Callier S, Snapyan M, Crom S, Prou D, Vincent J-D, Vernier P. Evolution and cell biology of dopamine receptors in vertebrates. Biol Cell 2003; 95: 489-502.
117. Bourne JA. SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev 2001; 7: 399-414.
118. 118. Briggs CA, Pollock NJ, Frail DE et al. Activation of the 5-HT1C receptor expressed in Xenopus oocytes by the benzazepines SCH 23390 and SKF 38393. Br J Pharmacol 1991; 104:1038-44.
119. Millan MJ, Newman-Tancredi A, Quentric Y, Cussac D. The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin 2C receptors. Psychopharmacology 2001; 156: 58-62.
120. Bronstein DM, Hong JS. Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality. J Pharmacol Exp Ther 1995; 274: 943-50.
121. Sonsalla PK, Gibb JW, Hanson GR. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther 1986; 238: 932-7.
122. Broening HW, Morford LL, Vorhees CV. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse (New York, N.Y.) 2005; 56: 84-93.
123. O'Dell SJ, Weihmuller FB, Marshall JF. Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: attenuation by dopamine D1 or D2 antagonists. J Neurochem 1993; 60: 1792-9.
124. Xu W, Zhu JPQ, Angulo JA. Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors. Synapse (New York, N.Y.) 2005; 58: 110-21.
125. Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE. Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther 2000; 295: 1077-85.
126. Angulo JA, Angulo N, Yu J. Antagonists of the neurokinin-1 or dopamine D1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum. Ann N Y Acad Sci 2004; 1025: 171-80.
127. Jayanthi S, Deng X, Ladenheim B et al. Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc Natl Acad Sci USA 2005; 102: 868-73.
128. Chen J, Rusnak M, Luedtke RR, Sidhu A. D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem 2004; 279: 39317-30.
129. Beauvais G, Atwell K, Jayanthi S, Ladenheim B, Cadet JL. Involvement of dopamine receptors in binge methamphetamine-induced activation of endoplasmic reticulum and mitochondrial stress pathways. PLoS One 2011; 6: e28946.
130. Kvernmo T, Härtter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 28: 1065-78.
131. Ito M, Numachi Y, Ohara A, Sora I. Hyperthermic and lethal effects of methamphetamine: roles of dopamine D1 and D2 receptors. Neurosci Lett 2008; 438: 327-9.
132. Gross NB, Duncker PC, Marshall JF. Striatal dopamine D1 and D2 receptors: widespread influences on methamphetamine-induced dopamine and serotonin neurotoxicity. Synapse (New York, N.Y.) 2011; 65: 1144-55.
133. Xie T, McCann UD, Kim S, Yuan J, Ricaurte GA. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J Neurosci 2000; 20: 7838-45.
134. Kil HY, Zhang J, Piantadosi CA. Brain temperature alters hydroxyl radical production during cerebral ischemia/reperfusion in rats. J Cereb Blood Flow Metab 1996; 16: 100-6.
135. Spencer JPE, Whiteman M, Jenner P, Halliwell B. 5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J Neurochem 2002; 81: 122-9.
136. Bowyer JF, Davies DL, Schmued L et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 1994; 268: 1571-80.
137. Tata DA, Raudensky J, Yamamoto BK. Augmentation of methamphetamine-induced toxicity in the rat striatum by unpredictable stress: contribution of enhanced hyperthermia. Eur J Neurosci 2007; 26: 739-48.
138. Hsu S-F, Niu K-C, Lin C-L, Lin M-T. Brain cooling causes attenuation of cerebral oxidative stress, systemic inflammation, activated coagulation, and tissue ischemia/injury during heatstroke. Shock (Augusta, Ga.) 2006; 26: 210-20.
139. Thomas DM, Francescutti-Verbeem DM, Kuhn DM. The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J Neurochem 2008; 105: 605-16.
140. Bull DR, Palij P, Sheehan MJ et al. Application of fast cyclic voltammetry to measurement of electrically evoked dopamine overflow from brain slices in vitro. J Neurosci Methods 1990; 32: 37-44.
141. Wightman RM, Zimmerman JB. Control of dopamine extracellular concentration in rat striatum by impulse flow and uptake. Brain Res Brain Res Rev 1990; 15: 135-44.
142. Volz TJ, Hanson GR, Fleckenstein AE. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. J Neurosci Methods 2006; 155: 109-15.
143. Jaber M, Dumartin B, Sagné C et al. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Eur J Neurosci 1999; 11: 3499-511.
144. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 1998; 95: 4029-34.
145. Tinsley RB, Bye CR, Parish CL et al. Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol 2009; 66: 472-84.
146. Mark KA, Soghomonian J-J, Yamamoto BK. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci 2004; 24: 11449-56.
147. Guillot TS, Shepherd KR, Richardson JR et al. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. J Neurochem 2008; 106: 2205-17.
148. Eisch AJ, Marshall JF. Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse (New York, N.Y.) 1998; 30: 433-45.
149. Chu P-W, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release. J Neurochem 2010; 115: 325-32.
150. Afonso-Oramas D, Cruz-Muros I, Alvarez de la Rosa D et al. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. Neurobiol Dis 2009; 36: 494-508.
151. Manning-Boǧ AB, Caudle WM, Perez XA et al. Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol Dis 2007; 27: 141-50.
152. Dickinson SD, Sabeti J, Larson GA et al. Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem 1999; 72: 148-56.